Ketamine for head and neck neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 May 2015: Trial registered, NCT02442739
  2. 15 Aug 2016: Trial started, NCT02442739
  3. 6 Nov 2018: Trial withdrawn, NCT02442739

The trials

NCT02442739: Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers

State
Withdrawn before it started
Phase
Early Phase 1
People
0 taking part
Started
15 Aug 2016
Primary completion
3 Nov 2017
Arms
Ketamine
Results
None posted
  1. 13 May 2015: Trial registered
  2. 15 Aug 2016: Trial started
  3. 6 Nov 2018: Trial withdrawn

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Kind of treatment: Drug.

Also known as 0.2 mg/kg ketamine, 1st perfusion of ketamine, 2nd perfusion of ketamine, Anaket v, Calypsol, CLORKETAM 1000, IMALGENE 1000, Intranasal Ketamine (IN), Intranasal ketamine, Ketafol component ketamine, KETASOL 100, Ketamine Infusion, Narketan, Tekam, Ursotamin, Vetaket.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.